Literature DB >> 23494037

Retinal vasoproliferative tumors: comparative clinical features of primary vs secondary tumors in 334 cases.

Carol L Shields1, Swathi Kaliki, Saad Al-Dahmash, Duangnate Rojanaporn, Shripaad Y Shukla, Brad Reilly, Jerry A Shields.   

Abstract

OBJECTIVE: To compare the clinical features of primary vs secondary retinal vasoproliferative tumors (VPTs).
METHODS: Retrospective case series of 334 tumors in 295 eyes of 275 patients.
RESULTS: Of 275 patients with VPT, 41% (n = 113) were male and 59% (n = 162) were female, with a mean age of 44 years at presentation. Primary VPT occurred in 80% (n = 219) and secondary VPT, in 20% (n = 56) of patients. Secondary VPT (n = 67) occurred in eyes with retinitis pigmentosa (n = 15, 22%), pars planitis (n = 14, 21%), Coats disease (n = 11, 16%), previous retinal detachment surgery (n = 8, 12%), idiopathic peripheral retinal vasculitis (n = 4, 6%), familial exudative vitreoretinopathy (n = 3, 4%), and others (n = 12, 18%). The mean interval between diagnosis of underlying ocular condition and secondary VPT was 160 months. Statistically significant differences (P < .05) in clinical features (primary vs secondary VPTs) included mean age at presentation (46 vs 38 years), visual symptoms (74% vs 87%), poor visual acuity worse than 20/200 (15% vs 28%), bilaterality (4% vs 20%), multifocality (5% vs 15%), postequatorial tumor location (20% vs 33%), tumor basal dimension (6 vs 7 mm), anterior chamber cells (16% vs 30%), and vitreous cells (19% vs 48%).
CONCLUSIONS: Retinal vasoproliferative tumor can be primary (80%) or secondary (20%). Compared with primary VPT, secondary VPT is more often bilateral, multiple, and larger and occurs at an earlier age associated with poorer visual acuity.

Entities:  

Mesh:

Year:  2013        PMID: 23494037     DOI: 10.1001/2013.jamaophthalmol.524

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  27 in total

1.  Tocilizumab for retinal vasoproliferative tumor secondary to juvenile idiopathic arthritis-associated uveitis: a case report.

Authors:  Alfredo Adán; Marina Mesquida; Victor Llorenç; Consuelo Modesto
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-09-24       Impact factor: 3.117

Review 2.  MANAGEMENT OF RETINAL HEMANGIOBLASTOMA IN VON HIPPEL-LINDAU DISEASE.

Authors:  Henry E Wiley; Valerie Krivosic; Alain Gaudric; Michael B Gorin; Carol Shields; Jerry Shields; Mary E Aronow; Emily Y Chew
Journal:  Retina       Date:  2019-12       Impact factor: 4.256

3.  Pseudoangiomatous retinal gliosis (PARG) treated with iodine plaque in patient with chronic retinal detachment.

Authors:  Marilyn A Marquez; Jorge Fortun; Prashanth Iyer; J William Harbour; Luis J Haddock
Journal:  Am J Ophthalmol Case Rep       Date:  2022-06-11

4.  Macular sequelae in vasoproliferative tumors: results of surgical approach.

Authors:  Asterios Diafas; Victoria Toumanidou; Ioannis Kassos; Maria Samouilidou; Anna Dastiridou; Nikolaos Ziakas; Sofia Androudi
Journal:  Int Ophthalmol       Date:  2021-06-25       Impact factor: 2.031

5.  Proliferative Vitreoretinopathy in Treated Retinoblastoma.

Authors:  Cindy S Hwang; Pia R Mendoza; Jill R Wells; Hans E Grossniklaus; G Baker Hubbard
Journal:  Ophthalmol Retina       Date:  2017 Mar-Apr

6.  Reactive Retinal Astrocytic Tumor (Focal Nodular Gliosis): Report of the Clinical Spectrum of 3 Cases.

Authors:  Arun D Singh; Hansell Soto; Claudine Bellerive; Charles V Biscotti
Journal:  Ocul Oncol Pathol       Date:  2017-03-23

7.  CyberKnife Stereotactic Radiotherapy in Secondary Vasoproliferative Tumor of the Retina.

Authors:  Şefik Can İpek; Murat Tunç; Kaan Oysul; Aylin Yaman; Ali Osman Saatci
Journal:  Case Rep Ophthalmol       Date:  2021-04-19

8.  Retinal vasoproliferative tumour-induced intractable neovascular glaucoma in a child with neurofibromatosis type 1.

Authors:  Deepika C Parameswarappa; Abhilasha Arvind Alone; Padmaja Kumari Rani
Journal:  BMJ Case Rep       Date:  2020-08-26

9.  VASOPROLIFERATIVE TUMORS IN INTERMEDIATE UVEITIS.

Authors:  Francesco Pichi; Piergorgio Neri; Aniruddha Agarwal; Alessandro Invernizzi; Netan Choudhry; Radgonde Amer; Andrea Lembo; Paolo Nucci; Ian Thompson; H Nida Sen; Carol L Shields
Journal:  Retina       Date:  2020-09       Impact factor: 3.975

10.  A novel mutation in the NR2E3 gene associated with Goldmann-Favre syndrome and vasoproliferative tumor of the retina.

Authors:  George J Manayath; Prasanthi Namburi; Sundaresan Periasamy; Jeevan A Kale; Venkatapathy Narendran; Anuradha Ganesh
Journal:  Mol Vis       Date:  2014-05-29       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.